Evidence map›Paper›PMID 37773001›Full record

ReviewGlobal spine journal2024

Cellular Bone Matrix in Spine Surgery - Are They Worth the Risk: A Systematic Review.

Mark J Lambrechts, Tariq Z Issa, Aditya Mazmudar, Yunsoo Lee, Gregory R Toci, Nicholas D D'Antonio, Meghan Schilken, Kenneth Lingenfelter, Christopher K Kepler, Gregory D Schroeder and 1 more

Abstract readReview
In one paragraph

Review in Global spine journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Synthetic osteobiologics in spine surgery: a review.Turkish journal of medical sciences · 2025
    Review
  5. Article
  6. Trends in spinal implant utilization and pricing.Journal of craniovertebral junction & spine
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mark J LambrechtsRothman Orthopaedic Institute at Thomas Jefferson University, Philadelphia, PA, USA.ORCID 0000-0002-9106-2228
Tariq Z IssaRothman Orthopaedic Institute at Thomas Jefferson University, Philadelphia, PA, USA.ORCID 0000-0002-0978-5225
Aditya MazmudarRothman Orthopaedic Institute at Thomas Jefferson University, Philadelphia, PA, USA.
Yunsoo LeeRothman Orthopaedic Institute at Thomas Jefferson University, Philadelphia, PA, USA.ORCID 0000-0002-6039-5142
Gregory R TociRothman Orthopaedic Institute at Thomas Jefferson University, Philadelphia, PA, USA.ORCID 0000-0003-4770-3507
Nicholas D D'AntonioRothman Orthopaedic Institute at Thomas Jefferson University, Philadelphia, PA, USA.ORCID 0000-0001-8484-0207
Meghan SchilkenRothman Orthopaedic Institute at Thomas Jefferson University, Philadelphia, PA, USA.
Kenneth LingenfelterDepartment of Orthopaedic Surgery, ChristianaCare, Wilmington, DE, USA.
Christopher K KeplerRothman Orthopaedic Institute at Thomas Jefferson University, Philadelphia, PA, USA.
Gregory D SchroederRothman Orthopaedic Institute at Thomas Jefferson University, Philadelphia, PA, USA.
Alexander R VaccaroRothman Orthopaedic Institute at Thomas Jefferson University, Philadelphia, PA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

STUDY

designSystematic Review.

objectiveTo review the literature for complications and outcomes after the implantation of cellular bone matrix (CBM) during spine fusion.

methodsThe PubMed database was queried from inception to January 31, 2023 for any articles that discussed the role of and identified a specific CBM in spinal fusion procedures. Adverse events, reoperations, methods, and fusion rates were collected from all studies and reported.

resultsSix hundred articles were identified, of which 19 were included that reported outcomes of 7 different CBM products. Seven studies evaluated lumbar fusion, 11 evaluated cervical fusion, and 1 study reported adverse events of a single CBM product. Only 4 studies were comparative studies while others were limited to case series. Fusion rates ranged from 68% to 98.7% in the lumbar spine and 87% to 100% in the cervical spine, although criteria for radiographic fusion was variable. While 7 studies reported no adverse events, there was no strict consensus on what constituted a complication. One study reported catastrophic disseminated tuberculosis from donor contaminated CBM. The authors of 14 studies had conflicts of interest with either the manufacturer or distributor for their analyzed CBM.

conclusionsCurrent evidence regarding the use of cellular bone matrix as an osteobiologic during spine surgery is weak and limited to low-grade non-comparative studies subject to industry funding. While reported fusion rates are high, the risk of severe complications should not be overlooked. Further large clinical trials are required to elucidate whether the CBMs offer any benefits that outweigh the risks.

Indexed as

cellular bone matrixcomplicationsosteobiologicspseudarthrosisspine fusion

Identifiers

PMID37773001
PMCPMC11192114

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.